Prothena Corporation Equity 2024

Prothena Corporation Aktienanalyse

What does Prothena Corporation do?

Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Prothena Corporation's Equity

Prothena Corporation's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Prothena Corporation's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Prothena Corporation's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Prothena Corporation's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Prothena Corporation’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Prothena Corporation stock

What is the equity of Prothena Corporation this year?

Prothena Corporation has equity of 561.36 M USD this year.

What was the equity of Prothena Corporation compared to the previous year?

The equity of Prothena Corporation has increased/decreased by -9.75% decreased compared to the previous year.

What impact does a high equity have on investors of Prothena Corporation?

A high equity is advantageous for investors of Prothena Corporation as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Prothena Corporation?

A low equity can be a risk for investors of Prothena Corporation, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Prothena Corporation affect the company?

An increase in equity of Prothena Corporation can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Prothena Corporation affect the company?

A reduction in equity of Prothena Corporation can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Prothena Corporation?

Some factors that can affect the equity of Prothena Corporation include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Prothena Corporation so important for investors?

The equity of Prothena Corporation is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Prothena Corporation take to change the equity?

To change equity, Prothena Corporation can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Prothena Corporation pay?

Over the past 12 months, Prothena Corporation paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Prothena Corporation is expected to pay a dividend of 0 USD.

What is the dividend yield of Prothena Corporation?

The current dividend yield of Prothena Corporation is .

When does Prothena Corporation pay dividends?

Prothena Corporation pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Prothena Corporation?

Prothena Corporation paid dividends every year for the past 0 years.

What is the dividend of Prothena Corporation?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Prothena Corporation located?

Prothena Corporation is assigned to the 'Health' sector.

Wann musste ich die Aktien von Prothena Corporation kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Prothena Corporation from 8/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.

When did Prothena Corporation pay the last dividend?

The last dividend was paid out on 8/28/2024.

What was the dividend of Prothena Corporation in the year 2023?

In the year 2023, Prothena Corporation distributed 0 USD as dividends.

In which currency does Prothena Corporation pay out the dividend?

The dividends of Prothena Corporation are distributed in USD.